MarginsXMarginsX
Home › Markets › Health Care › ZNTL

Zentalis Pharmaceuticals Inc. (ZNTL)

ZNTL trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$1.60
-5.88% on the day
Market cap
$157.2M
Micro cap
Revenue · 2025
$0
-100.0% on 2024
Net income · 2025
-$137.1M

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1725160/000172516026000014/0001725160-26-000014-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerZNTL on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO year2020
SEC CIK0001725160
SEC industry codePharmaceutical Preparations
Incorporated inDELAWARE

Financials · 2025

LineValue
Revenue$0
Net income-$137.1M
Operating income-$152.8M
Net marginNeeds revenue and net income
Operating marginOperating income not reported
Revenue growth-100.0%
Cash$36.0M
Total assets$289.0M
P/E (computed)Net income was not positive
P/S (computed)Needs market cap and revenue

Warning signs

Cash runway
2.2 months
$24.0M cash at September 30, 2026
Share count, 1 year
+36.0%
2025-11-01 to 2026-11-04 · +38.9% over 3 years
Going-concern doubt
Yes
10-Q filed November 9, 2026
Insider net buying, 12 months
$12.8M
Through September 30, 2026
SignFindingSource
Going concernStates substantial doubt about continuing as a going concern.
"Substantial doubt about an entity's ability to continue as a going concern exists when relevant conditions and events, considered in the aggregate, indicate that it is probable that the entity will be unable to meet its obligations as they become due within one year from the financial statements issuance date."
10-Q 2026-11-09
Cash and burn$24.0M cash; operating cash flow -$33.5M a quarter.Report 2026-09-30
Shares outstanding98,265,863 (2026-11-04); 72,250,779 a year earlier; 70,765,771 three years earlier.Cover page 2026-11-04
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 2 424B5 takedowns, 2 at the marketLatest 2026-08-14
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorErnst & Young LLP, San Diego, California, United StatesPCAOB Form AP 2026-04-10
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $22.9M, sold $10.1M on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
Not filed-$28.8M-$32.7M$24.0MNo debt tagsNeeds four quarters10-Q 2026-11-09
Q2 2026
2026-06-30
Not filed-$42.3M-$37.2M$24.8MNo debt tagsNeeds four quarters10-Q 2026-08-06
Q1 2026
2026-03-31
Not filed-$35.4M-$33.0M$31.9MNo debt tagsNeeds four quarters10-Q 2026-05-12
Q4 2025
2025-12-31
$0-$35.2M-$30.9M$36.0MNo debt tags$010-K 2026-03-26
Q3 2025
2025-09-30
$0-$26.7M-$27.0M$39.1MNo debt tags$26.9M10-Q 2025-11-10
Q2 2025
2025-06-30
$0-$26.9M-$34.7M$37.6MNo debt tags$26.9M10-Q 2025-08-06
Q1 2025
2025-03-31
$0-$48.3M-$32.6M$41.9MNo debt tags$26.9M10-Q 2025-05-14
Q4 2024
2024-12-31
$26.9M-$47.5M-$39.7M$33.9MNo debt tags$67.4M10-K 2026-03-26

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B52026-08-14
Latest annual report10-K2026-03-26
Latest quarterly / interim10-Q2026-11-09
Latest current report8-K2026-11-09
Latest proxyDEFA14A2026-05-27

Source: SEC EDGAR submissions feed, 550 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-1.2%
1 month-29.2%
3 months-59.0%
Year to date+25.9%
1 year+28.8%
From 52-week high-74.3%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
BBOTBridgeBio Oncology Therapeutics Inc. Common Stock$1.98-7.48%$158.9M
ADCTADC Therapeutics SA Common Shares$1.25-6.72%$159.7M
ABEOAbeona Therapeutics Inc.$2.60+7.44%$148.6M
ELDNEledon Pharmaceuticals Inc.$1.97-6.86%$166.4M
PRQRProQR Therapeutics N.V.$1.18-16.31%$166.5M
VRXAVeraxa Biotech AG$1.04-5.86%$147.8M
PYXSPyxis Oncology Inc.$1.41-10.76%$168.6M
ORMPOramed Pharmaceuticals Inc.$3.90+5.12%$169.6M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier